Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease | MicrobiomeTrials← Back to trialsNCT02675959
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2017-07-01Est. Completion: 2026-12
Enrollment target: 40 participants Locations- University of California Los Angeles, Los Angeles, California, United States
- University of Florida, Gainesville, Florida, United States
- New York Medical College, Valhalla, New York, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Sickle Cell Disease, Hemolytic Anemia
Background:
Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cell…
Bethesda, United StatesEst. completion Apr 27, 2027
Sickle Cell DiseasePulmonary DiseaseRenal DiseaseHeart Disease
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400…
Washington D.C., United StatesEst. completion Nov 2026